BackTable / Urology / Podcast / Episode #219

GU ASCO Highlights: Key Takeaways for Clinicians

with Dr. Ben Maughan & Dr. Shilpa Gupta

Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting.

This podcast is supported by:

Photocure

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

GU ASCO Highlights: Key Takeaways for Clinicians with Dr. Ben Maughan & Dr. Shilpa Gupta on the BackTable Urology Podcast

Ep 219 GU ASCO Highlights: Key Takeaways for Clinicians with Dr. Ben Maughan & Dr. Shilpa Gupta

00:00 / 01:04

BackTable, LLC (Producer). (2025, March 11). Ep. 219 – GU ASCO Highlights: Key Takeaways for Clinicians [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Shilpa Gupta

Dr. Shilpa Gupta is the director of Genitourinary Medical Oncology at Taussig Cancer Institute and co-leader of the Genitourinary Program at the Cleveland Clinic in Cleveland, Ohio.

Dr. Ben Maughan

Dr. Ben Maughan is a genitourinary oncologist at Huntsman Cancer Institute in Salt Lake City, Utah.

Dr. Bogdana Schmidt

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Synopsis

First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice.

Timestamps

00:00 - Introduction
09:20 - TALAPRO-2 Trial Insights
19:29 - Bladder Cancer: Immuno-Oncology Combinations and HER2
27:42 - NIAGARA and iNDUCT Trials
33:32 - Future Directions in Upper Tract Treatment
37:38 - Biomarkers in Kidney Cancer: KIM-1
46:43 - COSMIC-313: Triplet Therapy in Renal Cell Carcinoma
52:39 - Concluding Thoughts and Future Directions

Resources

Photocure:
https://www.photocure.com/

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

Up Next

Urothelial Carcinoma: Consolidative Surgery & Treatment Approaches with Dr. Abhinav Khanna on the BackTable Urology Podcast

Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle on the BackTable Urology Podcast

Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor on the BackTable Urology Podcast

Genomic Classifiers in Bladder Cancer Management with Dr. Carissa Chu on the BackTable Urology Podcast

Shared Decision Making in GU Cancer Management with Dr. Hung-Jui "Ray" Tan on the BackTable Urology Podcast

Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Upper Tract Urothelial Carcinoma (UTUC) Podcasts

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.